Georgetown Lombardi Comprehensive Cancer Center | Strategic Alliance Partners

Latest from Georgetown Lombardi Comprehensive Cancer Center


FDA Approval of Fruquintinib Expands Later-Line Treatment Options in mCRC

November 17, 2023

John Lindsay Marshall, MD, sheds light on the significance of the FDA approval of fruquintinib for patients with heavily pretreated metastatic colorectal cancer and discusses the efficacy and safety data from the FRESCO and FRESCO-2 trials that supported the decision in this population.

Dr Liu on the Significance of T-DXd For Patients With HER2-Mutant NSCLC and Brain Metastases

October 31, 2023

Stephen V. Liu, MD, discusses the significance of using fam-trastuzumab deruxtecan-nxki in patients with HER2-mutant non–small cell lung cancer and brain metastases according to pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials.

Luminary Awards Highlight Exemplary Work of Experts in GI Cancers

October 18, 2023

OncLive® and The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, have announced the winners of the 2023 Luminary Award in GI cancers.

Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy

October 12, 2023

Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outpatient administration of this modality at John Theurer Cancer Center, and future considerations for using this treatment approach in solid tumors.